NEW YORK – While diagnostic test makers have come to rely on antibodies for test development – a whole class of tests, immunodiagnostics, are based on antibodies – issues around them have been known for decades with industry and researchers working to solve them.
Against that backdrop, one firm, Avacta, has developed an alternative to antibodies with a technology called Affimers, and according to company officials, a growing number of diagnostic companies are exploring the use of the reagents.
Read the full article at 360Dx. (log in required)